Evaluation of splenic accumulation and colocalization of immature reticulocytes and Plasmodium vivax in asymptomatic malaria: A prospective human splenectomy study.
Journal
PLoS medicine
ISSN: 1549-1676
Titre abrégé: PLoS Med
Pays: United States
ID NLM: 101231360
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
27
09
2020
accepted:
19
04
2021
entrez:
26
5
2021
pubmed:
27
5
2021
medline:
26
8
2021
Statut:
epublish
Résumé
A very large biomass of intact asexual-stage malaria parasites accumulates in the spleen of asymptomatic human individuals infected with Plasmodium vivax. The mechanisms underlying this intense tropism are not clear. We hypothesised that immature reticulocytes, in which P. vivax develops, may display high densities in the spleen, thereby providing a niche for parasite survival. We examined spleen tissue in 22 mostly untreated individuals naturally exposed to P. vivax and Plasmodium falciparum undergoing splenectomy for any clinical indication in malaria-endemic Papua, Indonesia (2015 to 2017). Infection, parasite and immature reticulocyte density, and splenic distribution were analysed by optical microscopy, flow cytometry, and molecular assays. Nine non-endemic control spleens from individuals undergoing spleno-pancreatectomy in France (2017 to 2020) were also examined for reticulocyte densities. There were no exclusion criteria or sample size considerations in both patient cohorts for this demanding approach. In Indonesia, 95.5% (21/22) of splenectomy patients had asymptomatic splenic Plasmodium infection (7 P. vivax, 13 P. falciparum, and 1 mixed infection). Significant splenic accumulation of immature CD71 intermediate- and high-expressing reticulocytes was seen, with concentrations 11 times greater than in peripheral blood. Accordingly, in France, reticulocyte concentrations in the splenic effluent were higher than in peripheral blood. Greater rigidity of reticulocytes in splenic than in peripheral blood, and their higher densities in splenic cords both suggest a mechanical retention process. Asexual-stage P. vivax-infected erythrocytes of all developmental stages accumulated in the spleen, with non-phagocytosed parasite densities 3,590 times (IQR: 2,600 to 4,130) higher than in circulating blood, and median total splenic parasite loads 81 (IQR: 14 to 205) times greater, accounting for 98.7% (IQR: 95.1% to 98.9%) of the estimated total-body P. vivax biomass. More reticulocytes were in contact with sinus lumen endothelial cells in P. vivax- than in P. falciparum-infected spleens. Histological analyses revealed 96% of P. vivax rings/trophozoites and 46% of schizonts colocalised with 92% of immature reticulocytes in the cords and sinus lumens of the red pulp. Larger splenic cohort studies and similar investigations in untreated symptomatic malaria are warranted. Immature CD71+ reticulocytes and splenic P. vivax-infected erythrocytes of all asexual stages accumulate in the same splenic compartments, suggesting the existence of a cryptic endosplenic lifecycle in chronic P. vivax infection. Findings provide insight into P. vivax-specific adaptions that have evolved to maximise survival and replication in the spleen.
Sections du résumé
BACKGROUND
A very large biomass of intact asexual-stage malaria parasites accumulates in the spleen of asymptomatic human individuals infected with Plasmodium vivax. The mechanisms underlying this intense tropism are not clear. We hypothesised that immature reticulocytes, in which P. vivax develops, may display high densities in the spleen, thereby providing a niche for parasite survival.
METHODS AND FINDINGS
We examined spleen tissue in 22 mostly untreated individuals naturally exposed to P. vivax and Plasmodium falciparum undergoing splenectomy for any clinical indication in malaria-endemic Papua, Indonesia (2015 to 2017). Infection, parasite and immature reticulocyte density, and splenic distribution were analysed by optical microscopy, flow cytometry, and molecular assays. Nine non-endemic control spleens from individuals undergoing spleno-pancreatectomy in France (2017 to 2020) were also examined for reticulocyte densities. There were no exclusion criteria or sample size considerations in both patient cohorts for this demanding approach. In Indonesia, 95.5% (21/22) of splenectomy patients had asymptomatic splenic Plasmodium infection (7 P. vivax, 13 P. falciparum, and 1 mixed infection). Significant splenic accumulation of immature CD71 intermediate- and high-expressing reticulocytes was seen, with concentrations 11 times greater than in peripheral blood. Accordingly, in France, reticulocyte concentrations in the splenic effluent were higher than in peripheral blood. Greater rigidity of reticulocytes in splenic than in peripheral blood, and their higher densities in splenic cords both suggest a mechanical retention process. Asexual-stage P. vivax-infected erythrocytes of all developmental stages accumulated in the spleen, with non-phagocytosed parasite densities 3,590 times (IQR: 2,600 to 4,130) higher than in circulating blood, and median total splenic parasite loads 81 (IQR: 14 to 205) times greater, accounting for 98.7% (IQR: 95.1% to 98.9%) of the estimated total-body P. vivax biomass. More reticulocytes were in contact with sinus lumen endothelial cells in P. vivax- than in P. falciparum-infected spleens. Histological analyses revealed 96% of P. vivax rings/trophozoites and 46% of schizonts colocalised with 92% of immature reticulocytes in the cords and sinus lumens of the red pulp. Larger splenic cohort studies and similar investigations in untreated symptomatic malaria are warranted.
CONCLUSIONS
Immature CD71+ reticulocytes and splenic P. vivax-infected erythrocytes of all asexual stages accumulate in the same splenic compartments, suggesting the existence of a cryptic endosplenic lifecycle in chronic P. vivax infection. Findings provide insight into P. vivax-specific adaptions that have evolved to maximise survival and replication in the spleen.
Identifiants
pubmed: 34038413
doi: 10.1371/journal.pmed.1003632
pii: PMEDICINE-D-20-04714
pmc: PMC8154101
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1003632Subventions
Organisme : Wellcome Trust
ID : 200909
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 200909/Z/16/Z
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 099875
Pays : United Kingdom
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
PLoS Med. 2008 Jun 17;5(6):e128
pubmed: 18563962
Blood. 1959 May;14(5):558-63
pubmed: 13651329
Antimicrob Agents Chemother. 2008 Mar;52(3):1040-5
pubmed: 18180357
Clin Infect Dis. 2013 Feb;56(3):383-97
pubmed: 23087389
Lancet. 1997 Apr 19;349(9059):1178
pubmed: 9113040
PLoS One. 2013 Oct 08;8(10):e76062
pubmed: 24116088
Malar J. 2017 Feb 23;16(1):88
pubmed: 28231817
Antimicrob Agents Chemother. 2015 Jul;59(7):4206-14
pubmed: 25941228
J Infect Dis. 2022 Apr 1;225(7):1274-1283
pubmed: 32556188
PLoS Med. 2017 Aug 29;14(8):e1002379
pubmed: 28850568
Sci Rep. 2018 May 29;8(1):8308
pubmed: 29844356
Nat Commun. 2020 Jun 2;11(1):2761
pubmed: 32487994
PLoS Negl Trop Dis. 2016 Aug 10;10(8):e0004912
pubmed: 27509168
Clin Infect Dis. 2019 Jan 1;68(1):51-60
pubmed: 29771281
PLoS Negl Trop Dis. 2017 Apr 6;11(4):e0005365
pubmed: 28384192
Blood. 2021 Apr 29;137(17):2285-2298
pubmed: 33657208
Malar J. 2008 Dec 11;7 Suppl 1:S9
pubmed: 19091043
Cell Microbiol. 2012 Mar;14(3):386-400
pubmed: 22103402
J Clin Microbiol. 2014 Sep;52(9):3303-9
pubmed: 24989601
PLoS One. 2013 Aug 29;8(8):e71539
pubmed: 24009663
BMC Med. 2015 Mar 20;13:57
pubmed: 25889040
Ultrastruct Pathol. 2009 Oct;33(5):236-42
pubmed: 19895296
J Clin Pathol. 1962 May;15:254-9
pubmed: 13904914
PLoS Med. 2021 May 26;18(5):e1003567
pubmed: 34038421
J Health Soc Behav. 2004 Dec;45(4):441-52
pubmed: 15869115
Am J Trop Med Hyg. 2009 Feb;80(2):194-8
pubmed: 19190212
Proc Natl Acad Sci U S A. 2020 Jun 9;117(23):13056-13065
pubmed: 32439708
PLoS One. 2016 Oct 27;11(10):e0165340
pubmed: 27788243
Am J Trop Med Hyg. 2007 Nov;77(5):984-91
pubmed: 17984364
Science. 2018 Jan 5;359(6371):48-55
pubmed: 29302006
BMC Med. 2014 Nov 18;12:217
pubmed: 25406857
J Clin Microbiol. 2006 Jun;44(6):2307-10
pubmed: 16757648
Malar J. 2017 Sep 18;16(1):375
pubmed: 28923058
Malar J. 2015 Dec 23;14:520
pubmed: 26701778
PLoS Negl Trop Dis. 2012;6(8):e1772
pubmed: 22880143
Int J Parasitol. 2012 Nov;42(12):1063-70
pubmed: 23032102
Adv Parasitol. 2012;80:151-201
pubmed: 23199488
Br J Haematol. 1971 Jul;21(1):83-94
pubmed: 5559481
Am J Trop Med Hyg. 2001 Nov;65(5):614-22
pubmed: 11716124
J Infect Dis. 2004 Jan 15;189(2):190-4
pubmed: 14722882
PLoS Pathog. 2015 Jan 08;11(1):e1004558
pubmed: 25569250
Ann Trop Med Parasitol. 1997 Jul;91(5):501-16
pubmed: 9329987
Emerg Infect Dis. 2010 Oct;16(10):1611-4
pubmed: 20875292
Cancer. 1989 Apr 15;63(8):1539-43
pubmed: 2924261
Trans R Soc Trop Med Hyg. 2001 Nov-Dec;95(6):677-80
pubmed: 11816444
Int J Environ Res Public Health. 2019 May 31;16(11):
pubmed: 31159165
N Engl J Med. 2021 May 27;384(21):2067-2069
pubmed: 34042394
Trends Parasitol. 2020 Jun;36(6):560-570
pubmed: 32407682
Clin Microbiol Rev. 2013 Jan;26(1):36-57
pubmed: 23297258
Exp Parasitol. 1995 Mar;80(2):260-71
pubmed: 7895836
PLoS Negl Trop Dis. 2012;6(12):e1934
pubmed: 23272256
Blood. 2006 May 1;107(9):3745-52
pubmed: 16384927
Blood Adv. 2017 Feb 14;1(6):407-416
pubmed: 29296956
Malar J. 2017 Jan 13;16(1):29
pubmed: 28086789
PLoS Med. 2008 Jun 17;5(6):e127
pubmed: 18563961
Parasitology. 1999 Aug;119 ( Pt 2):127-33
pubmed: 10466119
Sci Transl Med. 2014 Jul 9;6(244):244re5
pubmed: 25009232
Am J Physiol. 1970 Mar;218(3):647-53
pubmed: 5414022
Can J Physiol Pharmacol. 1972 May;50(5):400-6
pubmed: 4114314
Blood. 2011 Feb 24;117(8):e88-95
pubmed: 21163923
Am J Hematol. 2016 Sep;91(9):875-82
pubmed: 27194638
Infect Immun. 2005 Apr;73(4):1986-94
pubmed: 15784539
J Infect Dis. 2009 Feb 1;199(3):445-50
pubmed: 19090777
Intern Med J. 2008 May;38(5):349-56
pubmed: 18284463
Blood. 2008 Sep 15;112(6):2520-8
pubmed: 18579796
Am J Trop Med Hyg. 1999 Apr;60(4):687-92
pubmed: 10348249
Int J Parasitol. 2004 Dec;34(13-14):1547-54
pubmed: 15582531
Clin Infect Dis. 2012 Oct;55(8):e67-74
pubmed: 22772803
Blood. 2007 Jul 1;110(1):18-28
pubmed: 17341664
Proc Natl Acad Sci U S A. 2007 May 29;104(22):9213-7
pubmed: 17517609
Mol Biochem Parasitol. 1993 Oct;61(2):315-20
pubmed: 8264734
mBio. 2018 May 8;9(3):
pubmed: 29739900
Ann ICRP. 2009;39(2):1-164
pubmed: 19897132
Blood. 2015 Feb 19;125(8):1314-24
pubmed: 25414440
Malar J. 2012 Aug 20;11:285
pubmed: 22905863
Blood Cancer J. 2018 Nov 19;8(12):119
pubmed: 30455416
J Infect Dis. 2002 May 15;185(10):1538-41
pubmed: 11992295